Craig E. Hunsaker Sells 50,000 Shares of Alphatec Holdings Inc (NASDAQ:ATEC) Stock

Share on StockTwits

Alphatec Holdings Inc (NASDAQ:ATEC) EVP Craig E. Hunsaker sold 50,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $5.75, for a total transaction of $287,500.00. Following the completion of the sale, the executive vice president now owns 811,112 shares in the company, valued at approximately $4,663,894. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Craig E. Hunsaker also recently made the following trade(s):

  • On Wednesday, May 15th, Craig E. Hunsaker sold 50,000 shares of Alphatec stock. The stock was sold at an average price of $4.50, for a total transaction of $225,000.00.

Shares of ATEC stock opened at $5.94 on Thursday. Alphatec Holdings Inc has a 12-month low of $1.18 and a 12-month high of $6.35. The company has a quick ratio of 1.40, a current ratio of 2.45 and a debt-to-equity ratio of 3.59. The stock has a 50 day moving average of $4.84. The stock has a market capitalization of $372.77 million, a PE ratio of -10.24 and a beta of 1.47.

Alphatec (NASDAQ:ATEC) last issued its earnings results on Wednesday, July 24th. The medical technology company reported ($0.21) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by ($0.05). Alphatec had a negative return on equity of 211.15% and a negative net margin of 45.29%. The company had revenue of $27.32 million during the quarter, compared to analysts’ expectations of $25.37 million. On average, analysts predict that Alphatec Holdings Inc will post -0.91 EPS for the current year.

ATEC has been the topic of several research reports. ValuEngine upgraded shares of Alphatec from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 8th. HC Wainwright raised their target price on shares of Alphatec from $4.00 to $6.00 and gave the stock a “buy” rating in a report on Tuesday, August 6th. Zacks Investment Research upgraded shares of Alphatec from a “sell” rating to a “hold” rating in a report on Monday, May 13th. BidaskClub upgraded shares of Alphatec from a “hold” rating to a “buy” rating in a report on Tuesday. Finally, Piper Jaffray Companies initiated coverage on shares of Alphatec in a report on Monday, August 5th. They issued an “overweight” rating and a $7.00 target price on the stock. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. Alphatec presently has a consensus rating of “Buy” and an average target price of $6.50.

Several institutional investors have recently modified their holdings of the company. Dimensional Fund Advisors LP boosted its stake in shares of Alphatec by 8.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 95,662 shares of the medical technology company’s stock worth $219,000 after acquiring an additional 7,705 shares during the last quarter. Advisor Group Inc. purchased a new position in shares of Alphatec during the 2nd quarter worth $36,000. JPMorgan Chase & Co. purchased a new position in shares of Alphatec during the 2nd quarter worth $36,000. Russell Investments Group Ltd. purchased a new position in shares of Alphatec during the 2nd quarter worth $40,000. Finally, Renaissance Technologies LLC boosted its stake in shares of Alphatec by 9.9% during the 2nd quarter. Renaissance Technologies LLC now owns 276,787 shares of the medical technology company’s stock worth $1,257,000 after acquiring an additional 25,000 shares during the last quarter. Institutional investors and hedge funds own 11.55% of the company’s stock.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, focuses on the design, development, and promotion of products for the surgical treatment of spine disorders. Its product portfolio and pipeline address the cervical, thoracolumbar, and intervertebral regions of the spine; and cover various spinal disorders and surgical procedures.

Featured Story: How does a 12b-1 fee affect fund performance?

Insider Buying and Selling by Quarter for Alphatec (NASDAQ:ATEC)

Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Greencore Group’s  Hold Rating Reiterated at Peel Hunt
Greencore Group’s Hold Rating Reiterated at Peel Hunt
GlaxoSmithKline  Given “Equal weight” Rating at Barclays
GlaxoSmithKline Given “Equal weight” Rating at Barclays
Bank of America Analysts Give GlaxoSmithKline  a GBX 1,900 Price Target
Bank of America Analysts Give GlaxoSmithKline a GBX 1,900 Price Target
HSBC Analysts Give International Consolidated Airlns Grp  a GBX 460 Price Target
HSBC Analysts Give International Consolidated Airlns Grp a GBX 460 Price Target
IMI  Coverage Initiated by Analysts at Berenberg Bank
IMI Coverage Initiated by Analysts at Berenberg Bank
ITV’s  “Buy” Rating Reiterated at Liberum Capital
ITV’s “Buy” Rating Reiterated at Liberum Capital


© 2006-2019 Ticker Report